Mallinckrodt plc company logo

# 1st Gen Model Mallinckrodt plc Pharmaceutical preparations

Subscribe >> Deal exit on
Dec. 18, 2017
Deal entry on
Dec. 18, 2017
2.12%Expected margin
66.22% successful of 74 deals
$23.36 Last close price
at 15-dec-2017
  • Top 20 Accuracy


Model's trade recommendations 1.08% Return for period

-5.96% Annual return

$2.27B Market Cap

β 1.30  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 1.08%
52wk return -17.07%
52wk Range
Sortino ratio 0.00
Sharpe ratio 0.00
Norm. RMSE 1.35%
Downside risk 29.03%
Volatility 33.20%
  • BUY Analysts consensus recommendation

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mallinckrodt plc (MNK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MNK model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 94M
P/E 3.22
Shares Outstanding 95M
% Held by Insiders 0.77%
% Held by Institutions 97.40%
EPS (last reported FY) $NaN
EPS (last reported Q) $1.97
EPS, estimated (last reported Q) $1.80
Total revenues $1 B
Net income $-0 B